| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/30/2005 | US20050143583 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 06/30/2005 | US20050143578 Compounds and methods |
| 06/30/2005 | US20050143569 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 06/30/2005 | US20050143468 administering amfenac or nepafenac; ophthalmic disorder, proliferative diabetic retinopathy, vision defects |
| 06/30/2005 | US20050143464 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts |
| 06/30/2005 | US20050143456 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 06/30/2005 | US20050143440 Excellent hypoglycemic agents for treating hyperglycemia, dyslipidemia, hypercholesterolemia, noninsulin-dependent type II diabetes, obesity, glucose intolerance, cardiovascular diabetic complications; reduced side effects due to absence of serotonin reuptake inhibition; imidazoline receptor pathologies |
| 06/30/2005 | US20050143438 N3 alkylated benzimidazole derivatives as MEk inhibitors |
| 06/30/2005 | US20050143430 Catechol bioisosteres |
| 06/30/2005 | US20050143414 reacting 2-chlorophenylacetic acid or ester with claimed intermediate N,N'-bis-4,5,6,7-tetrahydro-[3,2-c]-thienopyridyl methane which is solid and can be crystallized; optical purity; no byproducts |
| 06/30/2005 | US20050143405 Dipeptidyl peptidase inhibitors that lower plasma glucose; treatment and prophylaxis of diabetes, non-insulin dependent diabetes; 2-amino-3aminomethyl-4-phenylpyridines |
| 06/30/2005 | US20050143399 Novel compounds |
| 06/30/2005 | US20050143388 Nitric oxide donors for treatment of disease and injury |
| 06/30/2005 | US20050143368 Chemical compounds |
| 06/30/2005 | US20050143354 Association of an antithrombotic and aspirin |
| 06/30/2005 | US20050143322 Method for treating obesity |
| 06/30/2005 | US20050143312 Compositions and methods for promoting myocardial and peripheral angiogenesis |
| 06/30/2005 | US20050143305 sustained relese of saratin polypeptide to prevent platelet adhesion after vascular injury; thrombosis and restenosis inhibitor |
| 06/30/2005 | US20050143304 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 06/30/2005 | US20050143302 Inhibiting NF-kappa B-dependent target gene expression in a cell; fusions of a NEMO binding domain and a membrane translocation domain (third helix of antennapedia homeodomain or the HIV-1 Tat protein) |
| 06/30/2005 | US20050143298 Treating congestive heart failure by delivering a recombinant fibroblastic growth factor-2 or an angiogenically active fragment or an angiogenically active mutein by intravenous or intracoronary administration; benefit may last for up to six months |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142639 Nucleotide sequence with vectors and administering apolipoproteins with data documents for binding lipids and cubulin for treatment of cardiovascular disorders |
| 06/30/2005 | US20050142625 monoclonal antibodies or antigen-binding fragments having specific binding affinity to an epitope of protein kinases polypeptides, used for the diagnosis and treatment of various kinase-related diseases in humans |
| 06/30/2005 | US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 |
| 06/30/2005 | US20050142546 Assays for identifying modulators of rhomboid polypeptides |
| 06/30/2005 | US20050142535 Ogligonucleotides comprising alternating segments and uses thereof |
| 06/30/2005 | US20050142236 Composition comprising an aqueous extract of red vine leaves and a diuretic |
| 06/30/2005 | US20050142235 Preventing and/or alleviating leg discomfort from chronic venous insufficiency |
| 06/30/2005 | US20050142155 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 06/30/2005 | US20050142138 Endothelial cell expression patterns |
| 06/30/2005 | US20050142115 Papilloma pseudovirus and preparation |
| 06/30/2005 | US20050142110 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 06/30/2005 | CA2582611A1 Method of treating elevated plasma homocysteine levels in esrd patients |
| 06/30/2005 | CA2551944A1 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 06/30/2005 | CA2550012A1 Urea derivative, process for producing the same and use |
| 06/30/2005 | CA2549878A1 Glycosylation-deficient hepatocyte growth factor |
| 06/30/2005 | CA2549724A1 Use of treprostinil to treat and prevent ischemic lesions |
| 06/30/2005 | CA2549662A1 A method for the production of enriched hop extracts having combined oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | CA2549589A1 Prolinylarylacetamides |
| 06/30/2005 | CA2549001A1 Rifamycin analogs and uses thereof |
| 06/30/2005 | CA2548790A1 Medicinal compositions and combinations |
| 06/30/2005 | CA2548105A1 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 06/30/2005 | CA2547195A1 Microemulsion preconcentrate comprising a renin inhibitor |
| 06/29/2005 | EP1548121A1 Novel physiologically active substances |
| 06/29/2005 | EP1548032A1 Kdr peptides and vaccines comprising the same |
| 06/29/2005 | EP1548029A2 Peptid- and peptide mimetic derivatives having integrin inhibitor properties III |
| 06/29/2005 | EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/29/2005 | EP1548009A2 Process for the preparation of benzylimidazole derivatives and for losartan |
| 06/29/2005 | EP1548008A1 Compound having tgf-beta inhibitory activity and medicinal composition containing the same |
| 06/29/2005 | EP1547603A2 Compositions and methods for use in targeting vascular destruction |
| 06/29/2005 | EP1547600A1 Female hormone-containing patch |
| 06/29/2005 | EP1547597A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 06/29/2005 | EP1547591A1 Food improving blood flow |
| 06/29/2005 | EP1546704A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546375A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 06/29/2005 | EP1546373A2 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis |
| 06/29/2005 | EP1546369A2 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 06/29/2005 | EP1546172A2 Control sequences of the human corin gene |
| 06/29/2005 | EP1546167A1 Compounds that interact with kinases |
| 06/29/2005 | EP1546113A1 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
| 06/29/2005 | EP1546101A1 Naphthyl ether compounds and their use |
| 06/29/2005 | EP1546089A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 06/29/2005 | EP1546087A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 06/29/2005 | EP1546083A1 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them |
| 06/29/2005 | EP1545710A2 Therapeutic use |
| 06/29/2005 | EP1545643A1 Coated stent |
| 06/29/2005 | EP1545622A1 Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof |
| 06/29/2005 | EP1545609A2 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 06/29/2005 | EP1545589A1 A method of modulating endothelial cell activity |
| 06/29/2005 | EP1545585A1 Zinc transporter compositions for the treatment of cardiovascular diseases |
| 06/29/2005 | EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 06/29/2005 | EP1545550A2 Isosorbide mononitrate compositions and methods of their use |
| 06/29/2005 | EP1545538A2 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 06/29/2005 | EP1545527A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 06/29/2005 | EP1545523A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS |
| 06/29/2005 | EP1545488A1 Choline ascorbate formulations |
| 06/29/2005 | EP1545482A1 Novel nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same |
| 06/29/2005 | EP1545471A1 Storage stable tablets of fosinopril sodium |
| 06/29/2005 | EP1545287A2 Vasoregulating compounds and methods of their use |
| 06/29/2005 | EP1443948B1 Process for the preparation of anthocyanin-containing products |
| 06/29/2005 | EP1408943B1 Pharmaceutical formulation containing an ltb4 antagonist and a wetting agent |
| 06/29/2005 | EP1343786B1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 06/29/2005 | EP1315727B1 7-oxo pyridopyrimidines |
| 06/29/2005 | EP1289576B1 Drug combinations useful for prevention of restenosis |
| 06/29/2005 | EP1274701B1 [1,4']-bipiperidine compounds |
| 06/29/2005 | EP1272507B1 Integrin binding peptide derivatives |
| 06/29/2005 | EP1242069B1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 06/29/2005 | EP1239873B1 Use of fibrinolytic metalloproteinases for the therapeutic treatment of a blood clot |
| 06/29/2005 | EP1025216B1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 06/29/2005 | EP1021186B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha |
| 06/29/2005 | EP0735888B1 Purine compositions |
| 06/29/2005 | CN1633506A Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 06/29/2005 | CN1633498A Novel insulin/IGF/relaxin family polypeptides and dnas thereof |
| 06/29/2005 | CN1633444A 6-11 bicyclic ketolide derivatives |
| 06/29/2005 | CN1633437A Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 06/29/2005 | CN1633433A N-aroyl cyclic amines |
| 06/29/2005 | CN1633431A 喹唑啉衍生物类激酶抑制剂 Quinazoline derivatives kinase inhibitors |
| 06/29/2005 | CN1633428A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 06/29/2005 | CN1633421A Oxazole/thiazol-derivatives activators of the hppar-alpha receptor |